GlassScriptPhysician profile
Sharon Lott
NPI 1730568338
$2,359.07
in general payments reported to CMS, 2019-2025
15 companies · $645 in 2025
The $645 reported for 2025 was more than what 77% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $485 · 2022: $443 · 2023: $358 · 2024: $428 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,430.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $781.76 | 2021-2025 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $333.19 | 2021-2025 | |
| Idorsia Pharmaceuticals US INC | $284.62 | 2022-2023 | Quviviq |
| Novo Nordisk INC | $243.81 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $222.34 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Medtronic, INC. | $124.78 | 2025 | Symplicity G3 |
| Otsuka America Pharmaceutical, INC. | $88.50 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $58.55 | 2023-2025 | Auvelity |
| Gilead Sciences, INC. | $58.55 | 2025 | Epclusa |
| Astrazeneca Pharmaceuticals LP | $49.83 | 2022-2023 | Airsupra |
| Pfizer INC. | $36.00 | 2023-2024 | |
| Exact Sciences Corporation | $34.67 | 2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $19.75 | 2021 | |
| Biogen, INC. | $18.52 | 2025 | Skyclarys |
| Genentech USA, INC. | $4.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Lott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.